Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Миокардиты

Список литературы

  1. Maisch B., Pankuweit S. Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy // Herz. 2012. Vol. 37, № 6. P. 644–656.
  2. Caforio A.L.P. et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis // Eur. Heart J. 2007. Vol. 28, № 11. P. 1326– 1333.
  3. Kindermann I. et al. Predictors of Outcome in Patients With Suspected Myocarditis // Circulation. 2008. Vol. 118, № 6. P. 639–648.
  4. Mahrholdt H. et al. Cardiovascular Magnetic Resonance Assessment of Human Myocarditis: A Comparison to Histology and Molecular Pathology // Circulation. 2004. Vol. 109, № 10. P. 1250– 1258.
  5. Crişan S, Tint D, Petrescu L. Therapeutic Advances in Emer-gency Cardiology: A Focus on Acute Myocarditis. // Am J Ther. 2019;26(2):e294-e300..
  6. Schultheiss H.-P., Kuhl U., Cooper L.T. The management of myocarditis // Eur. Heart J. 2011. Vol. 32, № 21. P. 2616–2625.
  7. Kühl U. et al. Viral Persistence in the Myocardium Is Associated With Progressive Cardiac Dysfunction // Circulation. 2005. Vol. 112, № 13. P. 1965–1970.
  8. Bowles N.E. et al. Detection of viruses in myocardial tissues by polymerase chain reaction // J. Am. Coll. Cardiol. 2003. Vol. 42, № 3. P. 466–472.
  9. Magnani J.W. et al. Survival in biopsy-proven myocarditis: A long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors // Am. Heart J. 2006. Vol. 151, № 2. P. 463–470.
  10. Curigliano G. et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines // Ann. Oncol. 2012. Vol. 23, № suppl 7. P. vii155– vii166.
  11. Haas S.J. et al. Clozapine-Associated Myocarditis: A Review of 116 Cases of Suspected Myocarditis Associated with the Use of Clozapine in Australia During 1993???2003 // Drug Saf. 2007. Vol. 30, № 1. P. 47–57.
  12. Cook S.C. et al. Clozapine-Induced Myocarditis: Prevention and Considerations in Rechallenge // Psychosomatics. 2015. Vol. 56, № 6. P. 685–690.
  13. FEDERAL STATE BUDGETARY EDUCATIONAL INSTITUTION OF HIGHER EDUCATION, " et al. Exercise training in chronic heart failure: practical guidance of the Russian Heart Failure Society // Russ. Heart Fail. J. 2017. Vol. 18, № 1. P. 41–66.
  14. Cardiovascular Toxicity Induced by Chemotherapy, Targeted Agents and Radiotherapy: ESMO Clinical Practice Guidelines | ESMO [Electronic resource]. URL: https://www.esmo.org/Guidelines/Supportive-and-Palliative-Care/Cardiovascular-Toxicity- Induced-Chemotherapy-Targeted-Agents-and-Radiotherapy (accessed: 17.11.2019).
  15. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials // Cancer. 2003. Vol. 97, № 11. P. 2869–2879.
  16. Zawadowski G. et al. A contemporary case series of lupus myocarditis // Lupus. 2012. Vol. 21, № 13. P. 1378–1384.
  17. Mason J. Myocarditis and dilated cardiomyopathy An inflammatory link // Cardiovasc. Res. 2003. Vol. 60, № 1. P. 5–10.
  18. Gauntt C. Coxsackievirus experimental heart diseases // Front. Biosci. 2003. Vol. 8, № 5. P. e23- 35.
  19. Engler R.J.M. et al. A Prospective Study of the Incidence of Myocarditis/Pericarditis and New Onset Cardiac Symptoms following Smallpox and Influenza Vaccination // PLOS ONE / ed. Horwitz M.S. 2015. Vol. 10, № 3. P. e0118283.
  20. Pankuweit S., Ruppert V., Maisch B. Inflammation in dilated cardiomyopathy // Herz. 2004. Vol. 29, № 8. P. 788–793.
  21. Pankuweit S., Portig I., Maisch B. Pathophysiology of Cardiac Inflammation: Molecular Mechanisms // Herz. 2002. Vol. 27, № 7. P. 669–676.
  22. Maisch B. et al. Pathophysiology of viral myocarditis // Cardiovasc. Pathol. 2002. Vol. 11, № 2. P. 112–122.
  23. D’Ambrosio A. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review // Heart. 2001. Vol. 85, № 5. P. 499–504.
  24. Leone O. et al. 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology // Cardiovasc. Pathol. 2012. Vol. 21, № 4. P. 245–274.
  25. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies // Circulation. 1996. Vol. 93, № 5. P. 841–842.
  26. Mason J.W. et al. A Clinical Trial of Immunosuppressive Therapy for Myocarditis // N. Engl. J. Med. 1995. Vol. 333, № 5. P. 269–275.
  27. Felker G.M. et al. The Spectrum of Dilated Cardiomyopathy: The Johns Hopkins Experience with 1,278 Patients: // Medicine (Baltimore). 1999. Vol. 78, № 4. P. 270–283.
  28. Towbin J.A. et al. Incidence, Causes, and Outcomes of Dilated Cardiomyopathy in Children // JAMA. 2006. Vol. 296, № 15. P. 1867.
  29. 29. Cooper L.T. Myocarditis // N. Engl. J. Med. 2009. Vol. 360, № 15. P. 1526–1538.
  30. Vos T. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 // The Lancet. 2015. Vol. 386, № 9995. P. 743– 800.
  31. Maron B.J. et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology // Circulation. 2015. Vol. 132, № 22.
  32. Karjalainen J., Heikkilä J. Incidence of three presentations of acute myocarditis in young men in military service. A 20-year experience // Eur. Heart J. 1999. Vol. 20, № 15. P. 1120–1125.
  33. Регистр госпитализированных пациентов с декомпенсацией кровообращения (Павловский регистр). Сообщение 1. Современная клиническая характеристика пациента с декомпенсацией кровообращения. Клинические фенотипы пациентов [Electronic resource]. URL: https://elibrary.ru/item.asp?id=25276296 (accessed: 09.12.2019).
  34. Wakafuji S., Okada R. Twenty year autopsy statistics of myocarditis incidence in Japan. // Jpn. Circ. J. 1986. Vol. 50, № 12. P. 1288–1293.
  35. Gore I., Saphir O. Myocarditis // Am. Heart J. 1947. Vol. 34, № 6. P. 827–830.
  36. Basso C. Postmortem diagnosis in sudden cardiac death victims: macroscopic, microscopic and molecular findings // Cardiovasc. Res. 2001. Vol. 50, № 2. P. 290–300.
  37. Passarino G. et al. Prevalence of myocarditis at autopsy in Turin, Italy // Arch. Pathol. Lab. Med. 1997. Vol. 121, № 6. P. 619–622.
  38. Hufnagel G. et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID) // Herz. 2000. Vol. 25, № 3. P. 279–285.
  39. Kyto V., Sipila J., Rautava P. Gender differences in myocarditis: a nationwide study in Finland // Eur. Heart J. 2013. Vol. 34, № suppl_1.
  40. Kytö V., Sipilä J., Rautava P. The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood // Heart. 2013. Vol. 99, № 22. P. 1681–1684.
  41. Fairweather D., Cooper L.T., Blauwet L.A. Sex and Gender Differences in Myocarditis and Dilated Cardiomyopathy // Curr. Probl. Cardiol. 2013. Vol. 38, № 1. P. 7–46.
  42. Saji T. et al. Comparison of the Clinical Presentation, Treatment, and Outcome of Fulminant and Acute Myocarditis in Children // Circ. J. 2012. Vol. 76, № 5. P. 1222–1228.
  43. Caforio A.L.P. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases // Eur. Heart J. 2013. Vol. 34, № 33. P. 2636–2648.
  44. Schultz J.C. et al. Diagnosis and Treatment of Viral Myocarditis // Mayo Clin. Proc. 2009. Vol. 84, № 11. P. 1001–1009.
  45. Adams O. et al. Frequency and quantity of the parvovirus B19 genome in endomyocardial biopsies from patients with suspected myocarditis or idiopathic left ventricular dysfunction // Z. F. Kardiologie. 2004. Vol. 93, № 4. P. 300–309.
  46. Kühl U. et al. High Prevalence of Viral Genomes and Multiple Viral Infections in the Myocardium of Adults With “Idiopathic” Left Ventricular Dysfunction // Circulation. 2005. Vol. 111, № 7. P. 887–893.
  47. Kuethe F. et al. Prevalence of Parvovirus B19 and Human Bocavirus DNA in the Heart of Patients with no Evidence of Dilated Cardiomyopathy or Myocarditis // Clin. Infect. Dis. 2009. Vol. 49, № 11. P. 1660–1666.
  48. Stewart G.C. et al. Myocardial Parvovirus B19 Persistence: Lack of Association With Clinicopathologic Phenotype in Adults With Heart Failure // Circ. Heart Fail. 2011. Vol. 4, № 1. P. 71–78.
  49. Lassner D. et al. Myocarditis—Personalized Medicine by Expanded Endomyocardial Biopsy Diagnostics // World J. Cardiovasc. Dis. 2014. Vol. 04, № 06. P. 325–340.
  50. Pankuweit S. Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens // Hum. Pathol. 2003. Vol. 34, № 5. P. 497–503.
  51. Sabatine M.S. et al. Case 36-2007: A 31-Year-Old Woman with Rash, Fever, and Hypotension // N. Engl. J. Med. / ed. Cabot R.C. et al. 2007. Vol. 357, № 21. P. 2167–2178.
  52. Cooper L.T. et al. The role of endomyocardial biopsy in the management of cardiovascular disease: A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology // Eur. Heart J. 2007. Vol. 28, № 24. P. 3076–3093.
  53. Kindermann I. et al. Update on Myocarditis // J. Am. Coll. Cardiol. 2012. Vol. 59, № 9. P. 779– 792.
  54. Sagar S., Liu P.P., Cooper L.T. Myocarditis // Lancet Lond. Engl. 2012. Vol. 379, № 9817. P. 738– 747.
  55. Dennert R., Crijns H.J., Heymans S. Acute viral myocarditis // Eur. Heart J. 2008. Vol. 29, № 17. P. 2073–2082.
  56. McCarthy R.E. et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis // N. Engl. J. Med. 2000. Vol. 342, № 10. P. 690–695.
  57. William Dec G. Introduction to Clinical Myocarditis // Myocarditis: From Bench to Bedside / ed. Cooper L.T. Totowa, NJ: Humana Press, 2003. P. 257–281.
  58. Baccouche H. et al. Diagnostic synergy of non-invasive cardiovascular magnetic resonance and invasive endomyocardial biopsy in troponin-positive patients without coronary artery disease // Eur. Heart J. 2009. Vol. 30, № 23. P. 2869–2879.
  59. Frustaci A. et al. Myocarditis in hypertrophic cardiomyopathy patients presenting acute clinical deterioration // Eur. Heart J. 2007. Vol. 28, № 6. P. 733–740.
  60. Dec G.W. et al. Viral myocarditis mimicking acute myocardial infarction // J. Am. Coll. Cardiol. 1992. Vol. 20, № 1. P. 85–89.
  61. Ferreira V.M. et al. T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging // JACC Cardiovasc. Imaging. 2013. Vol. 6, № 10. P. 1048–1058.
  62. Abdel-Aty H. et al. Diagnostic Performance of Cardiovascular Magnetic Resonance in Patients With Suspected Acute Myocarditis // J. Am. Coll. Cardiol. 2005. Vol. 45, № 11. P. 1815–1822.
  63. van Nierop J., Limburg A., van Ofwegen-Hanekamp C.E.E. Myocarditis mimicking acute myocardial infarction // Neth. Heart J. 2015. Vol. 23, № 10. P. 502–504.
  64. Basman C. et al. Diagnostic Approach to Myocarditis Mimicking Myocardial Infarction at Initial Presentation // Cardiol. Res. 2016. Vol. 7, № 6. P. 209–213.
  65. Kühl U. et al. Parvovirus B19 Infection Mimicking Acute Myocardial Infarction // Circulation. 2003. Vol. 108, № 8. P. 945–950.
  66. Basic D., Gupta S., Kwong R.Y. Parvovirus B19-Induced Myocarditis Mimicking Acute Myocardial Infarction: Clarification of Diagnosis by Cardiac Magnetic Resonance Imaging // Circulation. 2010. Vol. 121, № 7.
  67. Collier R.J. Diphtheria toxin: mode of action and structure // Bacteriol. Rev. 1975. Vol. 39, № 1. P. 54–85.
  68. Stockins B.A. et al. Prognosis in patients with diphtheric myocarditis and bradyarrhythmias: assessment of results of ventricular pacing // Br. Heart J. 1994. Vol. 72, № 2. P. 190–191.
  69. Bethell D.B. et al. Prognostic value of electrocardiographic monitoring of patients with severe diphtheria // Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 1995. Vol. 20, № 5. P. 1259–1265.
  70. Mestroni L. et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy // Eur. Heart J. 1999. Vol. 20, № 2. P. 93–102.
  71. Brady W.J. et al. Myocarditis: emergency department recognition and management // Emerg. Med. Clin. North Am. 2004. Vol. 22, № 4. P. 865–885.
  72. Brown C.A., OʼConnell J.B. Implications of the Myocarditis Treatment Trial for clinical practice: // Curr. Opin. Cardiol. 1996. Vol. 11, № 3. P. 332–336.
  73. Deswal A. et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST) // Circulation. 2001. Vol. 103, № 16. P. 2055– 2059.
  74. Lauer B. et al. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis // J. Am. Coll. Cardiol. 2000. Vol. 35, № 1. P. 11–18.
  75. Heymans S. Myocarditis and heart failure: need for better diagnostic, predictive, and therapeutic tools // Eur. Heart J. 2007. Vol. 28, № 11. P. 1279–1280.
  76. deFilippi C.R. et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults // JAMA. 2010. Vol. 304, № 22. P. 2494–2502.
  77. Deardorff R., Spinale F.G. Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure // Biomark. Med. 2009. Vol. 3, № 5. P. 513–523.
  78. Emdin M. et al. Old and new biomarkers of heart failure // Eur. J. Heart Fail. 2009. Vol. 11, № 4. P. 331–335.
  79. Caforio A.L.P. et al. Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives // Circulation. 2007. Vol. 115, № 1. P. 76–83.
  80. Zhang L. et al. Autoantibodies against the myocardial beta1-adrenergic and M2-muscarinic receptors in patients with congestive heart failure // Chin. Med. J. (Engl.). 2002. Vol. 115, № 8. P. 1127–1131.
  81. Maisch B. et al. Inflammatory dilated cardiomyopathy (DCMI) // Herz. 2005. Vol. 30, № 6. P. 535–544.
  82. Frustaci Andrea et al. Immunosuppressive Therapy for Active Lymphocytic Myocarditis // Circulation. 2003. Vol. 107, № 6. P. 857–863.
  83. Staudt A. et al. Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy // J. Am. Coll. Cardiol. 2004. Vol. 44, № 4. P. 829–836.
  84. Störk S. et al. Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy // Am. Heart J. 2006. Vol. 152, № 4. P. 697–704.
  85. Warraich R.S. et al. Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3 and clinical correlates // Am. Heart J. 2002. Vol. 143, № 6. P. 1076–1084.
  86. Deubner N. et al. Cardiac beta1-adrenoceptor autoantibodies in human heart disease: rationale and design of the Etiology, Titre-Course, and Survival (ETiCS) Study // Eur. J. Heart Fail. 2010. Vol. 12, № 7. P. 753–762.
  87. Mahfoud F. et al. Virus serology in patients with suspected myocarditis: utility or futility? // Eur. Heart J. 2011. Vol. 32, № 7. P. 897–903.
  88. Liu P. et al. Viral myocarditis: balance between viral infection and immune response // Can. J. Cardiol. 1996. Vol. 12, № 10. P. 935–943.
  89. Klingel K. et al. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. // Proc. Natl. Acad. Sci. U. S. A. 1992. Vol. 89, № 1. P. 314–318.
  90. Baboonian C., Treasure T. Meta-analysis of the association of enteroviruses with human heart disease // Heart Br. Card. Soc. 1997. Vol. 78, № 6. P. 539–543.
  91. Mahrholdt H. et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis // Circulation. 2006. Vol. 114, № 15. P. 1581–1590.
  92. Grün S. et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery // J. Am. Coll. Cardiol. 2012. Vol. 59, № 18. P. 1604–1615.
  93. Ukena C. et al. Prognostic electrocardiographic parameters in patients with suspected myocarditis // Eur. J. Heart Fail. 2011. Vol. 13, № 4. P. 398–405.
  94. JCS Joint Working Group. Guidelines for diagnosis and treatment of myocarditis (JCS 2009): digest version // Circ. J. Off. J. Jpn. Circ. Soc. 2011. Vol. 75, № 3. P. 734–743.
  95. Yilmaz A. et al. Imaging in inflammatory heart disease: from the past to current clinical practice // Hell. J. Cardiol. HJC Hell. Kardiologike Epitheorese. 2009. Vol. 50, № 6. P. 449–460.
  96. Felker G.M. et al. Echocardiographic findings in fulminant and acute myocarditis // J. Am. Coll. Cardiol. 2000. Vol. 36, № 1. P. 227–232.
  97. Fields C.L. et al. Thallium-201 scintigraphy in the diagnosis and management of myocardial sarcoidosis // South. Med. J. 1990. Vol. 83, № 3. P. 339–342.
  98. Le Guludec D. et al. Myocardial sarcoidosis. Clinical value of technetium-99m sestamibi tomoscintigraphy // Chest. 1994. Vol. 106, № 6. P. 1675–1682.
  99. O’Connell J.B. et al. Gallium-67 imaging in patients with dilated cardiomyopathy and biopsy- proven myocarditis // Circulation. 1984. Vol. 70, № 1. P. 58–62.
  100. Ohira H., Tsujino I., Yoshinaga K. 18F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis // Eur. J. Nucl. Med. Mol. Imaging. 2011. Vol. 38, № 9. P. 1773–1783.
  101. Сафиуллина А.А. et al. Диагностические возможности магнитно-резонансной томографии сердца у больных с воспалительной кардиомиопатией: сопоставление результатов с данными эндомиокардиальной биопсии и клинической картиной // Терапевтический Архив. 2013. Vol. 85, № 4. P. 22–28.
  102. Puntmann V.O. et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy // JACC Cardiovasc. Imaging. 2013. Vol. 6, № 4. P. 475–484.
  103. Voigt A. et al. Cardiac magnetic resonance imaging in dilated cardiomyopathy in adults-- towards identification of myocardial inflammation // Eur. Radiol. 2011. Vol. 21, № 5. P. 925–935.
  104. Friedrich M.G. et al. Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper // J. Am. Coll. Cardiol. 2009. Vol. 53, № 17. P. 1475–1487.
  105. Kellman P. et al. Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method // J. Cardiovasc. Magn. Reson. 2012. Vol. 14, № 1. P. 63.
  106. Сафиуллина А.А. et al. Роль магнитно-резонансной томографии в диагностике воспалительных заболеваний миокарда // Кардиологический Вестник. 2012. Vol. 7, № 1 (19). P. 41–46.
  107. Röttgen R. et al. Magnetic resonance imaging findings in acute myocarditis and correlation with immunohistological parameters // Eur. Radiol. 2011. Vol. 21, № 6. P. 1259–1266.
  108. Luetkens J.A. et al. Comprehensive Cardiac Magnetic Resonance for Short-Term Follow-Up in Acute Myocarditis // J. Am. Heart Assoc. 2016. Vol. 5, № 7.
  109. Gutberlet M. et al. Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence // Radiology. 2008. Vol. 246, № 2. P. 401–409.
  110. Yilmaz A. et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance // Circulation. 2010. Vol. 122, № 9. P. 900–909.
  111. Chow L.H. et al. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis // J. Am. Coll. Cardiol. 1989. Vol. 14, № 4. P. 915–920.
  112. She R.C., Hammond E.H. Utility of immunofluorescence and electron microscopy in endomyocardial biopsies from patients with unexplained heart failure // Cardiovasc. Pathol. Off. J. Soc. Cardiovasc. Pathol. 2010. Vol. 19, № 4. P. e99-105.
  113. Deckers J.W., Hare J.M., Baughman K.L. Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center // J. Am. Coll. Cardiol. 1992. Vol. 19, № 1. P. 43–47.
  114. Shirani J., Freant L.J., Roberts W.C. Gross and semiquantitative histologic findings in mononuclear cell myocarditis causing sudden death, and implications for endomyocardial biopsy // Am. J. Cardiol. 1993. Vol. 72, № 12. P. 952–957.
  115. Holzmann M. et al. Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period // Circulation. 2008. Vol. 118, № 17. P. 1722–1728.
  116. Parrillo J.E. et al. The results of transvenous endomyocardial biopsy can frequently be used to diagnose myocardial diseases in patients with idiopathic heart failure. Endomyocardial biopsies in 100 consecutive patients revealed a substantial incidence of myocarditis // Circulation. 1984. Vol. 69, № 1. P. 93–101.
  117. Ponikowski P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC // Eur. Heart J. 2016. Vol. 37, № 27. P. 2129–2200.
  118. Mirabel M. et al. Outcomes, long-term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support // Crit. Care Med. 2011. Vol. 39, № 5. P. 1029–1035.
  119. Hsu K.-H. et al. Extracorporeal membranous oxygenation support for acute fulminant myocarditis: analysis of a single center’s experience // Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg. 2011. Vol. 40, № 3. P. 682–688.
  120. Nohria A., Mielniczuk L.M., Stevenson L.W. Evaluation and Monitoring of Patients with Acute Heart Failure Syndromes // Am. J. Cardiol. 2005. Vol. 96, № 6. P. 32–40.
  121. Forrester J.S., Diamond G.A., Swan H.J. Correlative classification of clinical and hemodynamic function after acute myocardial infarction // Am. J. Cardiol. 1977. Vol. 39, № 2. P. 137–145.
  122. Park J.H. et al. Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction // Heart Br. Card. Soc. 2010. Vol. 96, № 7. P. 533–538.
  123. Baronia AK, Azim A, Narula G, et al. Should early venous oximetry be indicated in suspected cases of fulminant myocarditis?. // BMJ. 1976. Vol. 1, № 6018. P. 1121–1123.
  124. Vital F.M.R., Ladeira M.T., Atallah A.N. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema // Am J Emerg Med. 2007;25(1):122-123.
  125. Park M. et al. Randomized, prospective trial of oxygen, continuous positive airway pressure, and bilevel positive airway pressure by face mask in acute cardiogenic pulmonary edema // Crit. Care Med. 2004. Vol. 32, № 12. P. 2407–2415.
  126. Felker G.M. et al. Diuretic strategies in patients with acute decompensated heart failure // N. Engl. J. Med. 2011. Vol. 364, № 9. P. 797–805.
  127. Ahmad T. et al. Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury // Circulation. 2018. Vol. 137, № 19. P. 2016–2028.
  128. Мареев В.Ю., Выгодин В.А., Беленков Ю.Н. ДиУруетическая терапия Эффективными дозами перораЛЬных диуретиков торасемида (Диувер®) и фуросемида в лечении больных с обострением Хронической Сердечной Недостаточности (ДУЭЛЬ-ХСН) // Журнал Сердечная Недостаточность. 2011. Vol. 12, № 1 (63). P. 3–10.
  129. DiNicolantonio J.J. Should torsemide be the loop diuretic of choice in systolic heart failure? // Future Cardiol. 2012. Vol. 8, № 5. P. 707–728.
  130. Murray M.D. et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure // Am. J. Med. 2001. Vol. 111, № 7. P. 513–520.
  131. Мареев Ю.В., Мареев В.Ю. Характеристика и лечение пациентов с ХСН, госпитализированных в стационар [Electronic resource]: Text.Serial.Journal // Кардиология. 2017. URL: https://lib.ossn.ru/jour/article/view/299 (accessed: 17.11.2019).
  132. Eapen Z.J. et al. Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: Findings from ASCEND-HF // Circ. Heart Fail. 2013. Vol. 6, № 4. P. 727–732.
  133. Hernandez A.F. et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure // JAMA. 2010. Vol. 303, № 17. P. 1716– 1722.
  134. Knauf H., Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states // J. Cardiovasc. Pharmacol. 1997. Vol. 29, № 3. P. 367–372.
  135. Martens P., Nijst P., Mullens W. Current Approach to Decongestive Therapy in Acute Heart Failure // Curr. Heart Fail. Rep. 2015. Vol. 12, № 6. P. 367–378.
  136. van Vliet A.A. et al. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor // Am. J. Cardiol. 1993. Vol. 71, № 3. P. 21A-28A.
  137. Butler J. et al. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure // JACC Heart Fail. 2016. Vol. 4, № 9. P. 726–735.
  138. Bart B.A. et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome // N. Engl. J. Med. 2012. Vol. 367, № 24. P. 2296–2304.
  139. Wakai A. et al. Nitrates for acute heart failure syndromes // Cochrane Database Syst. Rev. 2013. № 8. P. CD005151.
  140. Cotter G. et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema // Lancet Lond. Engl. 1998. Vol. 351, № 9100. P. 389–393.
  141. Belletti A. et al. The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials // Br. J. Anaesth. 2015. Vol. 115, № 5. P. 656–675.
  142. Mebazaa A. et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods // Intensive Care Med. 2011. Vol. 37, № 2. P. 290–301.
  143. Elkayam U. et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure // Am. Heart J. 2007. Vol. 153, № 1. P. 98–104.
  144. Cohn J.N. et al. A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart Failure // N. Engl. J. Med. 1998. Vol. 339, № 25. P. 1810–1816.
  145. Packer M. et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group // N. Engl. J. Med. 1991. Vol. 325, № 21. P. 1468–1475.
  146. De Backer D. et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock // N. Engl. J. Med. 2010. Vol. 362, № 9. P. 779–789.
  147. Giamouzis G. et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial // J. Card. Fail. 2010. Vol. 16, № 12. P. 922–930.
  148. Triposkiadis F.K. et al. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial // Int. J. Cardiol. 2014. Vol. 172, № 1. P. 115–121.
  149. Chen H.H. et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial // JAMA. 2013. Vol. 310, № 23. P. 2533– 2543.
  150. Matsumori A. et al. High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity // Jpn. Circ. J. 1999. Vol. 63, № 12. P. 934–940.
  151. Kivikko M. et al. Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients // Int. J. Cardiol. 2016. Vol. 215. P. 26–31.
  152. Packer M. et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure // JACC Heart Fail. 2013. Vol. 1, № 2. P. 103–111.
  153. Frustaci A., Russo M.A., Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study // Eur. Heart J. 2009. Vol. 30, № 16. P. 1995–2002.
  154. Chen H.S. et al. Corticosteroids for viral myocarditis // Cochrane Database Syst. Rev. / ed. Cochrane Heart Group. 2013.
  155. Priori S.G. et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) // Eur. Heart J. 2015. Vol. 36, № 41. P. 2793–2867.
  156. V. Pavlicek, J. Wintrich, F. Mah-foud, et al. 650. Implanted cardioverter defibril-lator (ICD) therapy in patients with suspected myocarditis: time of implantation and oc-currence of ventricular ar-rhythmias // EP Europace, Volume 19, Issue suppl_3, 1 June 2017, Page iii128
  157. Chiale P. A. et al. Efficacy of amiodarone during long-term treatment of malignant ventricular arrhythmias in patients with chronic chagasic myocarditis //American heart journal. – 1984. – Т. 107. – №. 4. – С. 656-665.
  158. Heart Failure Society Of America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline // J. Card. Fail. 2006. Vol. 12, № 1. P. 10–38.
  159. Milton Packer, What causes sudden death in patients with chronic heart failure and a reduced ejection fraction?// European Heart Journal, Volume 41, Issue 18, 7 May 2020, Pages 1757–1763
  160. Rezkalla S. et al. Effect of metoprolol in acute coxsackievirus B3 murine myocarditis // J. Am. Coll. Cardiol. 1988. Vol. 12, № 2. P. 412–414.
  161. Yuan Z. et al. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti- inflammatory effects associated with antioxidant property // Am. J. Physiol. Heart Circ. Physiol. 2004. Vol. 286, № 1. P. H83-90.
  162. Steinbeck, G., Bach, P., & Haberl, R. (1986). Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: Evaluation by programmed stimulation and ambulatory electrocardiogram.//Journal of the American College of Cardiology, 8(4), 949–958.
  163. Boutitie F. et al. Amiodarone Interaction With β-Blockers: Analysis of the Merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) Databases // Circulation. 1999. Vol. 99, № 17. P. 2268–2275.
  164. Kovoor P. et al. Comparison of sotalol with amiodarone for long-term treatment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease // Eur. Heart J. 1999. Vol. 20, № 5. P. 364–374.
  165. MacNeil D.J., Davies R.O., Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias // Am. J. Cardiol. 1993. Vol. 72, № 4. P. 44A-50A.
  166. Kandolin R. et al. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression // Circ. Heart Fail. 2013. Vol. 6, № 1. P. 15–22.
  167. Schumm J. et al. Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis // J. Cardiovasc. Magn. Reson. Off. J. Soc. Cardiovasc. Magn. Reson. 2014. Vol. 16. P. 14.
  168. Мареев В.Ю. et al. КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ ОССН - РКО - РНМОТ. СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ: ХРОНИЧЕСКАЯ (ХСН) И ОСТРАЯ ДЕКОМПЕНСИРОВАННАЯ (ОДСН). ДИАГНОСТИКА, ПРОФИЛАКТИКА И ЛЕЧЕНИЕ [Electronic resource]: Text.Serial.Journal // Кардиология. 2018. URL: https://lib.ossn.ru/jour/article/view/243 (accessed: 17.11.2019).
  169. Guglin, M., Nallamshetty, L. My-ocarditis: Diagnosis and Treat-ment. // Curr Treat Options Cardio Med 14, 637–651 (2012).
  170. Katz S.D. Left ventricular thrombus and the incidence of thromboembolism in patients with congestive heart failure: can clinical factors identify patients at increased risk? // J. Cardiovasc. Risk. 1995. Vol. 2, № 2. P. 97–102.
  171. Cioffi G. et al. Systemic thromboembolism in chronic heart failureA prospective study in 406 patients // Eur. Heart J. 1996. Vol. 17, № 9. P. 1381–1389.
  172. Fuster V. et al. The natural history of idiopathic dilated cardiomyopathy // Am. J. Cardiol. 1981. Vol. 47, № 3. P. 525–531.
  173. Stratton J R et al. Fate of left ventricular thrombi in patients with remote myocardial infarction or idiopathic cardiomyopathy. // Circulation. 1988. Vol. 78, № 6. P. 1388–1393.
  174. Howell M.D., Geraci J.M., Knowlton A.A. Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case-control study // J. Clin. Epidemiol. 2001. Vol. 54, № 8. P. 810–816.
  175. Carson P.E. et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group // Circulation. 1993. Vol. 87, № 6 Suppl. P. VI102-110.
  176. Lip G.Y.H. et al. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis // Thromb. Haemost. 2012. Vol. 108, № 6. P. 1009–1022.
  177. Samama M.M. et al. A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients // N. Engl. J. Med. 1999. Vol. 341, № 11. P. 793– 800.
  178. Turpie A.G. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial // Am. J. Cardiol. 2000. Vol. 86, № 12B. P. 48M-52M.
  179. Ageno W., Turpie A.G.G. Clinical trials of deep vein thrombosis prophylaxis in medical patients // Clin. Cornerstone. 2005. Vol. 7, № 4. P. 16–22.
  180. Konstantinides S.V. et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism / The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS) // Eur. Heart J. 2014. Vol. 35, № 43. P. 3033–3080.
  181. Agnelli G. et al. Apixaban for Extended Treatment of Venous Thromboembolism // N. Engl. J. Med. 2013. Vol. 368, № 8. P. 699–708.
  182. Agnelli G. et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism // N. Engl. J. Med. 2013. Vol. 369, № 9. P. 799–808.
  183. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism // N. Engl. J. Med. 2012. Vol. 366, № 14. P. 1287–1297.
  184. Homma S. et al. Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm // N. Engl. J. Med. 2012. Vol. 366, № 20. P. 1859–1869.
  185. Pelliccia A. et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology // Eur. Heart J. 2005. Vol. 26, № 14. P. 1422–1445.
  186. Basso C. et al. Myocarditis and dilated cardiomyopathy in athletes: diagnosis, management, and recommendations for sport activity // Cardiol. Clin. 2007. Vol. 25, № 3. P. 423–429, vi.
  187. Schultheiss H.-P. et al. Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy // Clin. Res. Cardiol. Off. J. Ger. Card. Soc. 2016. Vol. 105, № 9. P. 763–773.
  188. Kühl U. et al. Interferon-Beta improves survival in enterovirus-associated cardiomyopathy // J. Am. Coll. Cardiol. 2012. Vol. 60, № 14. P. 1295–1296.
  189. Orange J.S. et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology // J. Allergy Clin. Immunol. 2006. Vol. 117, № 4 Suppl. P. S525-553.
  190. Gullestad L. et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure // Circulation. 2001. Vol. 103, № 2. P. 220–225.
  191. Drucker N.A. et al. Gamma-globulin treatment of acute myocarditis in the pediatric population // Circulation. 1994. Vol. 89, № 1. P. 252–257.
  192. McNamara Dennis M. et al. Controlled Trial of Intravenous Immune Globulin in Recent-Onset Dilated Cardiomyopathy // Circulation. 2001. Vol. 103, № 18. P. 2254–2259.
  193. Herda L.R. et al. Effects of immunoadsorption and subsequent immunoglobulin G substitution on cardiopulmonary exercise capacity in patients with dilated cardiomyopathy // Am. Heart J. 2010. Vol. 159, № 5. P. 809–816.
  194. Bulut D. et al. Effect of protein A immunoadsorption on T cell activation in patients with inflammatory dilated cardiomyopathy // Clin. Res. Cardiol. Off. J. Ger. Card. Soc. 2010. Vol. 99, № 10. P. 633–638.
  195. Felix S.B. et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study // J. Am. Coll. Cardiol. 2000. Vol. 35, № 6. P. 1590–1598.
  196. Mobini R. et al. Hemodynamic improvement and removal of autoantibodies against beta1- adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy // J. Autoimmun. 2003. Vol. 20, № 4. P. 345–350.
  197. Legrand F., Klion A. Biologic Therapies Targeting Eosinophils: Current Status and Future Prospects // J. Allergy Clin. Immunol. Pract. 2015. Vol. 3, № 2. P. 167–174.
  198. Maisch B. Cardio-Immunology of Myocarditis: Focus on Immune Mechanisms and Treatment Options // Front. Cardiovasc. Med. 2019. Vol. 6. P. 48.
  199. Cooper L.T. et al. Usefulness of immunosuppression for giant cell myocarditis // Am. J. Cardiol. 2008. Vol. 102, № 11. P. 1535–1539.
  200. Brambatti M. et al. Eosinophilic Myocarditis: Characteristics, Treatment, and Outcomes // J. Am. Coll. Cardiol. 2017. Vol. 70, № 19. P. 2363–2375.
  201. Ammirati E. et al. Eosinophilic myocarditis: a paraneoplastic event // The Lancet. 2015. Vol. 385, № 9986. P. 2546.
  202. Akuthota P., Weller P.F. Spectrum of Eosinophilic End-Organ Manifestations // Immunol. Allergy Clin. North Am. 2015. Vol. 35, № 3. P. 403–411.
  203. Ogbogu P.U. et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy // J. Allergy Clin. Immunol. 2009. Vol. 124, № 6. P. 1319-1325.e3.
  204. Masi A.T. et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis) // Arthritis Rheum. 1990. Vol. 33, № 8. P. 1094–1100.
  205. Miszalski-Jamka T. et al. Noncorticosteroid Immunosuppression Limits Myocardial Damage and Contractile Dysfunction in Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome) // J. Am. Coll. Cardiol. 2015. Vol. 65, № 1. P. 103–105.
  206. Yanagisawa T. et al. Clinical significance of corticosteroid therapy for eosinophilic myocarditis // Int. Heart. J. 2011. Vol. 52, № 2. P. 110–113.
  207. Rothenberg M.E. et al. Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab // N. Engl. J. Med. 2008. Vol. 358, № 12. P. 1215–1228.
  208. Godsel L.M. et al. Captopril prevents experimental autoimmune myocarditis // J. Immunol. Baltim. Md 1950. 2003. Vol. 171, № 1. P. 346–352.
  209. Zhang Y.-Y. et al. Protective effects of losartan in mice with chronic viral myocarditis induced by coxsackievirus B3 // Life Sci. 2013. Vol. 92, № 24–26. P. 1186–1194.
  210. Saegusa S. et al. Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expression // Cardiovasc. Drugs Ther. 2007. Vol. 21, № 3. P. 155–160.
  211. Sukumaran V. et al. Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy // Exp. Biol. Med. Maywood NJ. 2010. Vol. 235, № 11. P. 1338–1346.
  212. Piepoli M.F., Crisafulli A. Pathophysiology of human heart failure: importance of skeletal muscle myopathy and reflexes // Exp. Physiol. 2014. Vol. 99, № 4. P. 609–615.
  213. Ribeiro J.P., Chiappa G.R., Callegaro C.C. The contribution of inspiratory muscles function to exercise limitation in heart failure: pathophysiological mechanisms // Rev. Bras. Fisioter. Sao Carlos Sao Paulo Braz. 2012. Vol. 16, № 4. P. 261–267.
  214. Davies E.J. et al. Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis // Eur. J. Heart Fail. 2010. Vol. 12, № 7. P. 706–715.
  215. Pandey A. et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials // Circ. Heart Fail. 2015. Vol. 8, № 1. P. 33–40.
  216. Corrà U. et al. Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology // Eur. J. Heart Fail. 2018. Vol. 20, № 1. P. 3–15.
  217. Bellet R.N., Adams L., Morris N.R. The 6-minute walk test in outpatient cardiac rehabilitation: validity, reliability and responsiveness--a systematic review // Physiotherapy. 2012. Vol. 98, № 4. P. 277–286.
  218. Арутюнов Г.П. Вопросы немедикаментозного лечения пациентов, страдающих сердечной недостаточностью // Журнал сердечная недостаточность. 2001. Vol. 2, № 1. P. 35.
  219. Callegaro C.C. et al. Augmented peripheral chemoreflex in patients with heart failure and inspiratory muscle weakness // Respir. Physiol. Neurobiol. 2010. Vol. 171, № 1. P. 31–35.
  220. Shah P. et al. Is Swimming Safe in Heart Failure? A Systematic Review // Cardiol. Rev. 2017. Vol. 25, № 6. P. 321–325.
  221. Zamora E. et al. Estimated creatinine clearance: a determinant prognostic factor in heart failure // Med Clin (Barc). 2008. Vol. 131, № 2. P. 47–51.
  222. Colwell L., Quinn L. Glycemic control and heart disease // Nurs Clin North Am. 2001. Vol. 36, № 2. P. 321–331, vii–viii.
  223. Ewid M. et al. AST/ALT ratio predicts the functional severity of chronic heart failure with reduced left ventricular ejection fraction // BMC Res Notes. 2020. Vol. 13, № 1. P. 178.
  224. Nishimura M., Nakayama K., Ishikawa Y. [Cardiac arrhythmias caused by electrolyte imbalance] // Nihon Rinsho. 1996. Vol. 54, № 8. P. 2207–2212.
  225. Avanzas P. et al. Multiple complex stenoses, high neutrophil count and C-reactive protein levels in patients with chronic stable angina // Atherosclerosis. 2004. Vol. 175, № 1. P. 151–157.
  226. Morici N. et al. [Relevance of complete blood count parameters in the assessment of acute coronary syndromes: a combined hematological and cardiological perspective] // G Ital Cardiol (Rome). 2019. Vol. 20, № 12. P. 694–705.
  227. Núñez J. et al. Low lymphocyte count and cardiovascular diseases // Curr Med Chem. 2011. Vol. 18, № 21. P. 3226–3233.
  228. Bonaque J.C. et al. Red blood cell distribution width adds prognostic value for outpatients with chronic heart failure // Rev Esp Cardiol (Engl Ed). 2012. Vol. 65, № 7. P. 606–612.
  229. Suh S. et al. Relationship between serum bilirubin levels and cardiovascular disease // PLoS One. 2018. Vol. 13, № 2. P. e0193041.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*